Gibson S L, Hilf R
Cancer Res. 1976 Oct;36(10):3736-41.
The estrogen-binding capacity of mammary tumors induced by 7,12-dimethylbenz(a)anthracene was measured in lesions from animals after the ovariectomy, deprival of insulin (diabetes), or treatment with lergotrile mesylate to inhibit prolactin secretion. The average estrogen-binding capacity was 30 fmoles/mg cytosol protein in growing or static carcinomas from intact (control) animals. A significant reduction in estrogen-binding capacity was observed in regressing but not static mammary tumors from ovariectomized animals. In regressing and static tumors from diabetic rats, estrogen-binding capacity was significantly lower than in lesions from intact animals; this effect was not seen in growing tumors from diabetic rats. Tumors that were growing or static in lergotrile-treated animals showed reduced capacity to bind labeled estradiol. The effects of duration of hormone treatment or time of tissue storage on estrogen-binding capacity were examined and did not appear to be correlated with the decreased binding in tumors from treated animals. The results suggest that hormones capable of producing altered neoplastic growth may influence the level of estrogen receptors.
在切除卵巢、剥夺胰岛素（糖尿病）或用甲磺酸麦角腈治疗以抑制催乳素分泌后的动物病变中，测量了由7,12-二甲基苯并(a)蒽诱导的乳腺肿瘤的雌激素结合能力。来自完整（对照）动物的生长或静止癌组织中，雌激素结合能力的平均值为30飞摩尔/毫克胞质溶胶蛋白。在去卵巢动物的消退但非静止乳腺肿瘤中，观察到雌激素结合能力显著降低。在糖尿病大鼠的消退和静止肿瘤中，雌激素结合能力显著低于完整动物的病变组织；在糖尿病大鼠的生长肿瘤中未观察到这种效应。在接受麦角腈治疗的动物中生长或静止的肿瘤显示出结合标记雌二醇的能力降低。研究了激素治疗持续时间或组织储存时间对雌激素结合能力的影响，这些影响似乎与经治疗动物肿瘤中结合能力的降低无关。结果表明，能够改变肿瘤生长的激素可能会影响雌激素受体水平。
